Alterity Therapeutics (ATHE) announced that new presentations related to its Multiple System Atrophy program were delivered at the American ...

As part of its ongoing commitment to environmental sustainability, Mynco has planned several additional activities to support China's National Tree Planting Day 2025. The company is dedicated to ...

Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) has announced promising new data from its Phase 2 trial of ATH434 in Multiple ...

Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announc ...

- New bioMUSE Data Informs ATH434-202 Study Endpoints - - Webcast to Include Key Opinion Leader, Daniel Claassen, M.D., M.S., ...

The ATH434-202 is an open label study designed to evaluate the safety, efficacy and target engagement of ATH434 in participants with advanced multiple system atrophy (MSA). “Following the positive ...

ATH434 is a Disease Modifying Drug Candidate Targeting Parkinsonian Disorders - - Topline Data Expected Mid-Year 2025 - MELBOURNE, Australia and SAN FRANCISCO, March 27, 2025 (GLOBE NEWSWIRE ...

Alterity Therapeutics (ASX:ATH, NASDAQ:ATHE) has announced the completion of its last patient visit in the ATH434-202 open-label Phase 2 clinical trial for multiple system atrophy (MSA), a rare ...

Alterity Therapeutics (ATHE) announced that the last patient in the ATH434-202 Phase 2 trial has completed the study. The ATH434-202 is an open ...

The ATH434-202 is an open label study designed to evaluate the safety, efficacy and target engagement of ATH434 in participants with advanced multiple system atrophy (MSA). “Following the ...